Arrowhead Pharma Stock Price, News & Analysis

Arrowhead Pharmaceuticals (NASDAQ: ARWR) reported its fiscal Q3 2025 results, highlighting significant progress in its pipeline with four candidates in Phase 3 studies. The company announced a major deal where its subsidiary Visirna Therapeutics will receive $130 million upfront from Sanofi, plus potential milestone payments of $265 million for plozasiran rights in Greater China.

Financial results showed revenue of $27.8 million and a net loss of $175.2 million ($1.26 per share). The company maintains a strong balance sheet with $900.4 million in total cash resources. Notable achievements include earning a $100 million milestone payment from Sarepta for ARO-DM1 progress, with potential for an additional $200 million milestone by year-end.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced that its majority-owned subsidiary Visirna Therapeutics has signed an asset purchase agreement with Sanofi for the rights to develop and commercialize plozasiran in Greater China. Sanofi will pay $130 million upfront and up to $265 million in potential regulatory milestone payments.

Plozasiran, a first-in-class RNA interference therapeutic targeting APOC3, is being developed to treat familial chylomicronemia syndrome (FCS) and severe hypertriglyceridemia. The drug has already completed a successful Phase 3 trial in Chinese FCS patients and received Breakthrough Therapy Designation and Priority Review from China's NMPA, with an NDA submitted and accepted in January 2025.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) has achieved a significant milestone in its collaboration with Sarepta Therapeutics (NASDAQ: SRPT), earning a $100 million payment. The milestone was triggered by reaching the first enrollment target in a Phase 1/2 clinical study of ARO-DM1, an RNAi therapeutic targeting type 1 myotonic dystrophy (DM1).

The company anticipates reaching a second enrollment target by the end of 2025, which would trigger an additional $200 million milestone payment. The current payment is expected to be received within 60 days, as per the license and collaboration agreement terms.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced the approval of inducement grants for 38 new employees by its Board of Directors on July 22, 2025. The grants, made under NASDAQ Listing Rule 5635(c)(4), consist of 52,680 restricted stock units in total. These equity awards, which are outside the company's stockholder-approved equity incentive plans, will vest over a four-year period on an annual basis.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) issued a statement regarding its Exclusive License and Collaboration Agreement with Sarepta Therapeutics. The agreement, closed in February 2025, included a $500 million upfront payment and $325 million through stock purchase at $27.25 per share.

The deal includes $250 million in annual installments over 5 years, $300 million in near-term payments for ARO-DM1 trial enrollment, and up to $10 billion in potential milestones plus tiered royalties. Despite Sarepta's recent unrelated setbacks and restructuring, they have prioritized Arrowhead's programs. The agreement includes comprehensive termination provisions that would return assets and IP to Arrowhead if Sarepta fails to meet its financial obligations.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) has announced it will host a webcast and conference call to discuss its fiscal 2025 third quarter financial results on August 7, 2025, at 4:30 p.m. ET. The quarter ended June 30, 2025.

The event will be accessible via live audio webcast through the Events and Presentations page in the Investors section of Arrowhead's website. A replay will be available approximately two hours after the call concludes. Analysts wishing to participate must pre-register through the provided registration link to receive dial-in details.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) has initiated the Phase 3 YOSEMITE clinical trial for zodasiran, its RNAi therapeutic targeting ANGPTL3 for treating homozygous familial hypercholesterolemia (HoFH). This rare genetic condition causes severely elevated LDL-cholesterol levels and early cardiovascular disease.

Zodasiran becomes Arrowhead's fourth RNAi candidate to reach late-stage pivotal studies, following plozasiran, fazirsiran (licensed to Takeda), and olpasiran (licensed to Amgen). Phase 2 results showed promising reductions in LDL-C, ApoB, non-HDL-C, and triglycerides in HoFH patients.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) has completed enrollment in three Phase 3 clinical studies (SHASTA-3, SHASTA-4, and MUIR-3) for plozasiran, targeting severe hypertriglyceridemia treatment. The studies, involving approximately 2,200 patients across 24 countries, are expected to complete by mid-2026 with topline data release shortly after. The company has already submitted an NDA for plozasiran based on positive Phase 3 PALISADE study results for familial chylomicronemia syndrome, with FDA's PDUFA date set for November 18, 2025. These trials represent significant progress in plozasiran's development pathway, focusing on triglyceride reduction at 12 months as the primary endpoint.

Arrowhead Pharmaceuticals (NASDAQ: ARWR) has initiated a Phase 1/2a clinical trial for ARO-ALK7, its novel RNAi therapeutic targeting obesity treatment. The study marks a significant milestone as ARO-ALK7 becomes the first RNAi therapeutic targeting adipose tissue genes to enter clinical trials. The drug, developed using Arrowhead's proprietary TRiM™ platform, works by silencing the Activin receptor-like kinase 7 (ALK7) in adipose tissue. Preclinical studies showed promising results, demonstrating reduced body weight and fat mass while preserving lean muscle. The trial will initially evaluate single and multiple escalating doses in healthy obese subjects as monotherapy, with plans to progress to combination studies with tirzepatide in obese patients with and without type 2 diabetes.